Exhibit
99.1
News Release
LANDAUER
Landauer,
Inc. Reports
Fiscal
2012 Second Quarter Results
Strong Revenue Growth Driven by Medical Physics
and Medical Products Segments
For Further Information Contact:
Jim Polson
FTI Consulting
Phone: 312-553-6730
Email: jim.polson@fticonsulting.com
GLENWOOD,
Ill.— May 7, 2012—Landauer, Inc. (NYSE: LDR), a recognized leader in personal and environmental radiation monitoring,
outsourced medical physics services and high
quality medical consumable accessories, today reported financial results for its fiscal 2012 second quarter ended March 31,
2012.
Fiscal 2012 Second Quarter Highlights
| ▪ |
|
Revenue grew 21 percent to $39.1 million, compared to prior year period. |
| ▪ |
|
Gross profit grew 11 percent to $23.1 million on increased revenue and improved business mix. |
| ▪ |
|
Operating income of $10.1 million includes $1.2 million of non-recurring acquisition ($0.3 million), IT platform enhancement ($0.3 million) and non-cash stock based compensation ($0.6 million) expenses. |
| ▪ |
|
Net income of $7.1 million, or $0.75 per diluted share, including $0.10 per diluted share, of acquisition, IT platform enhancement, and non-cash stock based compensation expenses. |
| ▪ |
|
Adjusted EBITDA of $14.9 million compared to $15.0 million in the prior year period. |
| ▪ |
|
Adjusted Free Cash Flow of $21.8 million, an 11 percent increase over prior year period. |
“We are pleased with the progress
we made across multiple initiatives during the quarter,” said Bill Saxelby, President and CEO of Landauer. “Our recently
acquired Medical Products business contributed strong results and the Medical Physics segment continues to show profit improvement.
We are on plan with our military initiatives and are well positioned to achieve our full year guidance as planned.”
- more -
| Landauer, Inc. 2 Science Road Glenwood, Illinois 60425-1586 Telephone: (708) 755-7000 Facsimile: (708) 755-7011 |
Landauer,
Inc.
Add
1
Second Fiscal Quarter Financial
Overview and Business Segment Results
Revenues for the second fiscal quarter of 2012
were $39.1 million, an increase of $6.8 million, or 20.9 percent compared with revenues of $32.3 million for the same quarter in
fiscal 2011. The Medical Physics segment contributed an increase of $2.9 million and the new Medical Products segment increased
revenues by $4.0 million. The Radiation Monitoring segment experienced a reduction of $0.1 million.
Gross margins were 59.0 percent for the second
fiscal quarter of 2012, compared with 64.1 percent for the second fiscal quarter of 2011. The decline in gross margin rate was
primarily due to an increase in Medical Physics segment revenues, which has lower margins compared to the Radiation Monitoring
and Medical Products segments, along with lower margin equipment sales in the quarter.
Total operating expenses for the second fiscal
quarter of 2012 were $12.9 million, an increase of $4.1 million, or 46.1 percent, compared with operating expenses of $8.8 million
for the same quarter in fiscal 2011. The operating expenses increase was due to $1.5 million associated with acquired companies
purchased subsequent to the prior year’s comparable quarter, $0.7 million due to timing of the recording of incentive compensation
expenses associated with improved operating performance in fiscal 2012 versus fiscal 2011, investment in research and development
in support of military and first responder initiatives, investment in customer facing organizations, and expenses related to the
company’s IT systems initiative. For the second fiscal quarter of 2012, total operating expenses before $0.3 million of non-recurring
acquisition expenses, $0.3 million of IT platform enhancement related expenses, and $0.6 million of non-cash stock based compensation
expenses were $11.7 million, for an operating margin of 29.9 percent of total revenues. This compares with the $8.0 million reported
for the second fiscal quarter of 2011, before $0.1 million of non-recurring acquisition expenses, $0.2 million of IT platform enhancement
related expenses, and $0.5 million of non-cash stock based compensation expenses, for an operating margin of 24.7 percent of total
revenues in the prior year period.
Operating income for the second fiscal quarter
of 2012 was $10.1 million, a decrease of $1.8 million, or 14.6 percent compared with operating income of $11.9 million for the
same quarter in fiscal 2011. The decrease in operating income was primarily driven by a decline of $4.1 million in the Radiation
Monitoring segment due principally to an increased mix of lower margin sales and higher operating expenses, offset by an increase
of $0.3 million in the Medical Physics segment, and the addition of the Medical Products segment which contributed $2.0 million
in operating income. Adjusted operating income, before non-recurring acquisition expenses, IT platform enhancement related expenses,
and non-cash stock based compensation expenses, for the second fiscal quarter of 2012 was $11.3 million, a 10.6 percent decrease
compared with adjusted operating income on a relative basis of $12.7 million for the second fiscal quarter of 2011.
Net other income for the second fiscal quarter
of 2012 was $0.2 million, a decrease of $0.3 million, or 63.9 percent, from the prior year quarter. An increase of $0.5 million
in the equity in income of joint ventures was offset by a $0.8 million increase in interest expense associated with borrowings
to acquire IZI in the first fiscal quarter of 2012.
The effective tax rate was 30.0 percent and
34.6 percent for the second fiscal quarters of 2012 and 2011, respectively. The decline in the effective tax rate was due primarily
to the cumulative effect of prior year foreign tax credits that were approved during the second fiscal quarter of 2012.
- more -
Landauer,
Inc.
Add
2
Net income for the second fiscal quarter ended
March 31, 2012 was $7.1 million, or $0.75 per diluted share. This represents a decrease of $0.9 million, or 11.1 percent, compared
with $8.0 million, or $0.85 per diluted share, for the second fiscal quarter of 2011. Excluding the costs associated with the acquisitions,
IT platform enhancement, and non-cash stock based compensation, net income was $8.0 million, as compared to $8.6 million in the
prior year period. The resulting diluted earnings per share for the second fiscal quarter of 2012 were $0.85, excluding $0.10 per
diluted share of acquisition, IT platform enhancement, and non-cash stock based compensation expenses. This compares with $0.91,
excluding $0.06 per diluted share of acquisition, IT platform enhancement, and non-cash stock based compensation expenses,
for the second fiscal quarter of 2011.
Earnings before interest, taxes, depreciation
and amortization (“EBITDA”) were $ 13.7 million, a 3.0 percent decrease compared with $14.1 million in the comparable
prior year period. The decrease was due primarily to higher cost of sales based on revenue mix and higher selling, general and
administrative expenses for the second fiscal quarter of 2012 partially offset by favorable equity in income of joint ventures.
Adjusted earnings before interest, taxes, depreciation and amortization, acquisition related expenses, IT platform enhancement
expenses, and non-cash stock based compensation expenses (“Adjusted EBITDA”) were $14.9 million, consistent with the
comparable prior year period. A reconciliation of net income to EBITDA and Adjusted EBITDA is included in the attached financial
exhibits.
Radiation
Monitoring Segment
Radiation
Monitoring revenues for the second fiscal quarter of 2012 decreased 0.6 percent, or $0.1 million, from the second fiscal
quarter of 2011 to $27.4 million. The slight decrease resulted from foreign exchange losses,
partially offset by International Radiation Monitoring organic revenues.
Radiation Monitoring operating income for the
second fiscal quarter of 2012 decreased to $8.0 million, a 33.5 percent decrease from $12.1 million in the comparable prior year
period. The decrease in operating income was primarily impacted by an increase in lower margin equipment sales both domestically
and internationally, and higher selling, general and administrative expenses. Selling, general and administrative costs for the
second fiscal quarter of 2012 increased 29.9 percent, or $2.2 million, from the comparable prior year period, to $9.6 million.
The increase was due primarily to a $0.7 million increase in compensation costs, consistent with operating performance expectations
and timing of short-term and long-term incentive plans, $0.3 million of increased professional fees, a $0.3 million increase in
research and development activities in connection with military and first responder initiatives, a $0.3 million increase from investment
in the Company’s customer facing organizations, a $0.2 million increase in employee benefit plan and medical expenses, a
$0.2 million increase due to the Company’s IT systems initiative, and $0.2 million of increased spending to support international
revenue growth.
Corporate
expenses for shared functions are recognized in the Radiation Monitoring segment where they have been reported historically. Radiation
Monitoring adjusted operating income, exclusive of the impact of acquisition related transaction expenses, IT platform enhancement
expenses, and non-cash stock based compensation expenses for the second fiscal quarter of 2012 decreased 28.3 percent, or $3.7
million, to $9.2 million compared with adjusted operating income of $12.9 million for fiscal 2011.
- more -
Landauer,
Inc.
Add
3
Medical
Physics Segment
Medical Physics revenues for the second fiscal
quarter of 2012 increased 60.2 percent, or $2.9 million, from the comparable period in 2011 to $7.7 million on $0.7 million of
organic growth and $2.2 million due to the impact of acquired companies. The Medical Physics segment operating income of $0.1 million,
or 1.4 percent of revenues, increased $0.3 million as compared to a loss of $0.2 million, or 4.0 percent of revenues, in the second
fiscal quarter of 2011. The improvement in operating income was primarily due to operating efficiencies in the organic Medical
Physics business and higher episodic equipment commissioning sales leveraging a relatively fixed cost structure, as well as higher
volume sales inclusive of acquired companies.
Medical
Products Segment
Medical
Products revenues for the second fiscal quarter of 2012 were $4.0 million. Medical Products operating income was $2.0 million or
49.7 percent of revenues for the second fiscal quarter of 2012. Given the acquisition of IZI was completed during the first quarter
of fiscal 2012, there is no direct comparison to the prior year quarter.
Fiscal Six Months Financial Overview and Business Segment Results
Revenues for the first six months of fiscal
2012 were $75.8 million, an increase of $15.0 million, or 24.7 percent compared with revenues of $60.8 million for the same period
in fiscal 2011. The Medical Physics segment and the Radiation Monitoring segment contributed an increase of $5.8 million and $3.0
million, respectively. The contribution of the new Medical Products segment increased revenue by $6.2 million.
Gross margins were 59.2 percent for the
first six months of fiscal 2012, compared with 62.7 percent for the first six months of fiscal 2011. The decline in gross margin
rate was primarily due to a shift in the mix of cost of sales resulting from the overall growth of the Medical Physics segment,
which has lower margins compared to the Radiation Monitoring and Medical Products segments, along with lower margin equipment sales.
Total operating
expenses for the first six months of fiscal 2012 were $27.1 million, an increase of $9.0 million, or 50.1 percent, compared with
operating expenses of $18.1 million for the same period in fiscal 2011. The operating expenses increase was due to $2.9
million associated with acquired companies purchased subsequent to the prior year’s comparable period, $1.0
million due to timing of the recording of incentive compensation expenses associated with improved operating performance in fiscal
2012 versus fiscal 2011, $0.5 million due to performance against incentive compensation plans, investment
in research and development in support of military and first responder initiatives, investment in customer facing organizations,
expenses supporting international growth, and expenses related to the Company’s IT systems
initiative. For the first six months of fiscal 2012, total operating expenses before $2.2
million of non-recurring acquisition expenses, $0.6 million of IT platform enhancement related expenses, and $1.4 million of non-cash
stock based compensation expenses were $22.9 million, for an operating margin of 30.3 percent of total revenues. This compares
with the $16.3 million reported for the first six months of fiscal 2011, before $0.2 million of non-recurring acquisition expenses,
$0.6 million of IT platform enhancement related expenses, and $1.0 million of non-cash stock based compensation expenses, for an
operating margin of 26.8 percent of total revenues in the prior year period.
- more -
Landauer,
Inc.
Add
4
Operating income for the first six months
of fiscal 2012 was $17.7 million, a decrease of $2.3 million, or 11.5 percent compared with operating income of $20.0 million for
the same period in fiscal 2011. The decrease in operating income was primarily driven by a $2.0 million increase in acquisition
costs incurred in the first fiscal quarter of 2012, which primarily related to the acquisition of IZI. An additional decline of
$4.4 million in Radiation Monitoring operating income, due primarily to the higher operating expenses, was offset partially by
an increase in operating income of $1.7 million in the Medical Physics segment and the addition of the Medical Products segment
which contributed $2.4 million in operating income. Adjusted operating income, before non-recurring acquisition expenses, IT platform
enhancement related expenses, and non-cash stock based compensation expenses, for the first six months of fiscal 2012 was $21.9
million, compared with adjusted operating income, on a relative basis, of $21.8 million for the first six months of fiscal 2011.
Net other income for the first six months
of fiscal 2012 was $0.5 million, a decrease of $0.7 million, or 59.1 percent, from the prior year period. An increase of $0.8 million
in the equity in income of joint ventures was offset by a $1.5 million increase in interest expense associated with borrowings
to acquire IZI in the first fiscal quarter of 2012.
The effective tax rate was 32.2 percent
and 33.2 percent for the first six months of fiscal 2012 and 2011, respectively.
Net income for the first six months of
fiscal 2012 was $12.0 million, a decrease of $1.8 million, or 12.9 percent compared with $13.8 million for the same period in fiscal
2011. Excluding the costs associated with the acquisitions, IT platform enhancement, and non-cash stock based compensation, net
income was $14.9 million, as compared to $15.0 million in the comparable prior year period. The resulting diluted earnings per
share for the six month period ended March 31, 2012 were $1.59 per share, excluding $0.32 per diluted share of acquisition, IT
platform enhancement, and non-cash stock based compensation expenses. This compares with $1.60 per share, excluding $0.13 per diluted
share of acquisition, IT platform enhancement, and non-cash stock based compensation expenses, for the six month period ended March 31,
2011.
EBITDA for the first six months of fiscal
2012 were $24.2 million, a 1.0 percent decrease compared with $24.4 million in the comparable prior year period. The decrease was
due primarily to higher cost of sales based on revenue mix and higher selling, general and administrative expenses for the first
six months of fiscal 2012, partially offset by favorable equity in income of joint ventures. Adjusted EBITDA for the first six
months of fiscal 2012 were $28.4 million, an 8.2 percent increase compared with $26.3 million in the comparable prior year period.
Adjusted Free Cash Flow (Adjusted EBITDA, plus or minus changes in working capital, less capital expenditures) was $21.8 million,
an 11.4 percent increase over the comparable prior year period of $19.6 million due principally to improved working capital partially
offset by increased capital expenditures. A reconciliation of net income to EBITDA, Adjusted EBITDA, and Adjusted Free Cash Flow
is included in the attached financial exhibits.
- more -
Landauer,
Inc.
Add
5
Radiation
Monitoring Segment
Radiation Monitoring revenues for the
first six months of fiscal 2012 increased 5.8 percent, or $3.0 million, from the first six months of fiscal 2011 to $54.4 million.
Of the increase, $2.1 million was related to the impact of higher equipment sales, primarily from the Company’s ongoing initiatives
with the military market. International Radiation Monitoring revenues increased 5.9 percent, or $0.9 million, from the comparable
prior year period, driven primarily by organic growth in most regions, including both equipment sales and service revenues.
Radiation Monitoring operating income
for the first six months of fiscal 2012 decreased to $14.3 million, a 30.7 percent decrease from $20.7 million in the comparable
prior year period, impacted by a $2.0 million increase in acquisition related expenses, primarily related to IZI, $0.3 million
from the increase in lower margin equipment sales both domestically and internationally, and higher selling, general and administrative
expenses. Selling, general and administrative costs for the first six months of fiscal 2012 increased 27.2 percent, or $4.1 million,
to $19.2 million. The increase was due primarily to a $1.5 million increase in compensation costs, consistent with operating performance
expectations and timing of short-term and long-term incentive plans, $0.5 million of increased spending to support international
revenue growth, a $0.5 million increase in employee benefit plan and medical expenses, a $0.4 million increase in research and
development activities in connection with the military and first responder initiatives, a $0.6 million investment in customer facing
organizations, and $0.3 million of increased professional fees.
Radiation Monitoring adjusted operating
income, exclusive of the impact of acquisition related transaction expenses, IT platform enhancement expenses, and non-cash stock
based compensation expenses for the first six months of fiscal 2012 decreased 17.5 percent, or $4.0 million, to $18.5 million compared
with adjusted operating income of $22.5 million for the comparable period in fiscal 2011.
Medical
Physics Segment
Medical Physics revenues for the first
six months of fiscal 2012 increased 62.0 percent, or $5.8 million, from the comparable period in 2011 to $15.1 million on $1.7
million of organic growth and $4.1 million due to the impact of acquired companies. The Medical Physics segment operating income
of $1.0 million, or 6.6 percent of revenues, increased $1.7 million as compared to a loss of $0.7 million, or 7.0 percent of revenues,
in the first six months of fiscal 2011. The improvement in operating income was primarily due to operating efficiencies in the
core Medical Physics business and higher episodic equipment commissioning sales leveraging a relatively fixed cost structure, as
well as higher volume sales inclusive of acquired companies.
- more -
Landauer,
Inc.
Add
6
Medical
Products Segment
Revenues
for the period from the date of acquisition through March 31, 2012 were $6.2 million. Medical Products operating income was $2.4
million or 38.2 percent of revenues for the same period. Given the acquisition of IZI was completed during the first quarter of
fiscal 2012, there is no direct comparison to the prior year six month period.
Balance Sheet
Landauer
ended the second fiscal quarter of 2012 with total assets of $284.4 million, an increase of $115.7 million compared to total assets
of $168.7 million at the end of fiscal 2011 due principally to the acquisition of IZI in November 2011. The Company completed the
quarter with $18.7 million of cash and cash equivalents on the balance sheet and unused borrowing capacity of $45.9 million under
its current $175 million credit facility, which provides adequate liquidity to meet its current and anticipated obligations. Adjusted
Free Cash Flow provided by operating activities for the six months ended March 31, 2012 was
$21.8 million, an increase of $2.2 million from the fiscal first half of 2012.
The increase benefited from a tax refund during the first half of fiscal 2012, which was partially offset by an increase in capital
expenditures.
Fiscal
2012 Outlook
Landauer’s
business plan for fiscal 2012 currently anticipates aggregate revenues for the year
to be in the range of $150 to $157 million, which includes 10 months of contributions
from the recent IZI acquisition. The business plan also anticipates:
| ▪ |
|
$4.2 million ($2.8 million net of tax) of non-recurring expense spending to support the successful completion of the Company’s IT Platform systems initiative and the related post implementation support. |
| ▪ |
|
Incremental depreciation and amortization over fiscal 2011 of $1.0 million ($0.7 million net of tax) related to the deployment of the final phase of the Company’s IT systems initiative in the third quarter of fiscal 2012. |
| ▪ |
|
The accretive impact of the November 2011 acquisition of IZI is anticipated to produce $1.1 million to $1.5 million of net income for the 10 months included in fiscal 2012. |
| ▪ |
|
The blended effective tax rate for the full fiscal year is anticipated to be within a range of 31 percent to 33 percent. |
Based
upon the above assumptions, the Company anticipates reported net income for fiscal 2012 in the range of $21 to $23 million and
Adjusted EBITDA expected for fiscal 2012 in the range of $53 to $57 million. In addition, the Company will begin to receive an
annual cash tax benefit of approximately $2 million as a result of the structure of the acquisition of IZI.
- more -
Landauer,
Inc.
Add
7
Conference Call Details
Landauer has scheduled its second quarter conference
call for investors over the Internet on Tuesday, May 8, 2012, at 9:00 a.m. Central Time (10 a.m. Eastern Time). To participate,
callers should dial 877-941-2332 (within the United States and Canada), or 480-629-9867 (international callers) about 10 minutes
before the presentation. To listen to a webcast on the Internet, please go to the Company’s website at http://www.landauerinc.com
at least 15 minutes early to register, download and install any necessary audio software. Investors may access a replay of
the call by dialing 800-406-7325 (within the United States and Canada), or 303-590-3030 (international callers), passcode 4534716#,
which will be available through Friday, June 8, 2012. The replay will also be available on Landauer’s website for 90 days
following the call.
About Landauer
Landauer is a leading global provider of technical
and analytical services to determine occupational and environmental radiation exposure and is the leading domestic provider of
outsourced medical physics services. For more than 50 years, the Company has provided complete radiation dosimetry services to
hospitals, medical and dental offices, universities, national laboratories, nuclear facilities and other industries in which radiation
poses a potential threat to employees. Landauer’s services include the manufacture of various types of radiation detection
monitors, the distribution and collection of the monitors to and from customers, and the analysis and reporting of exposure findings.
The Company provides its dosimetry services to approximately 1.7 million individuals globally. In addition, through its Global
Physics Solutions subsidiary, the Company provides therapeutic and imaging physics services to the medical physics community. Through
its IZI Medical Products subsidiary, the Company provides medical consumable accessories used in radiology, radiation therapy,
and image guided surgery procedures.
- more -
Landauer,
Inc.
Add
8
Safe Harbor Statement
Some of the information shared here (including,
in particular, the section titled “Fiscal 2012 Outlook”) constitutes forward-looking statements that are based on assumptions
and involve certain risks and uncertainties. These include the following, without limitation: assumptions, risks and uncertainties
associated with the Company’s development and introduction of new technologies in general; the ability to protect and utilize
the Company’s intellectual property; continued customer acceptance of the InLight technology; the adaptability of optically
stimulated luminescence (OSL) technology to new platforms and formats; military and other government funding for the purchase of
certain of the Company’s equipment and services; the impact on sales and pricing of certain customer group purchasing arrangements;
the costs associated with the Company’s research and business development efforts; the usefulness of older technologies and
related licenses and intellectual property; the effectiveness of and costs associated with the Company’s IT platform enhancements;
the anticipated results of operations of the Company and its subsidiaries or ventures; valuation of the Company’s long-lived
assets or business units relative to future cash flows; changes in pricing of products and services; changes in postal and delivery
practices; the Company’s business plans; anticipated revenue and cost growth; the ability to integrate the operations of
acquired businesses and to realize the expected benefits of acquisitions; the risks associated with conducting business internationally;
costs incurred for potential acquisitions or similar transactions; other anticipated financial events; the effects of changing
economic and competitive conditions; foreign exchange rates; government regulations; accreditation requirements; changes in the
trading market that affect the cost of obligations under the Company’s benefit plans; and pending accounting pronouncements.
These assumptions may not materialize to the extent assumed, and risks and uncertainties may cause actual results to be different
from what is anticipated today. These risks and uncertainties also may result in changes to the Company’s business plans
and prospects, and could create the need from time to time to write down the value of assets or otherwise cause the Company to
incur unanticipated expenses. Additional information may be obtained by reviewing the information
set forth in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended
September 30, 2011, and other reports filed by the Company from time to time with the Securities and Exchange Commission.
Financial Tables Follow
- more -
Landauer,
Inc.
Add
9
LANDAUER, INC. AND SUBSIDIARIES
Consolidated Statements of Income (Unaudited)
| |
|
|
|
|
|
|
|
|
|
|
|
| |
Three Months Ended
March 31, |
|
Six Months Ended
March 31, |
| (Dollars in Thousands, Except per Share) |
2012 |
|
2011 |
|
2012 |
|
2011 |
| Net revenues |
$ |
39,094 |
|
$ |
32,327 |
|
$ |
75,763 |
|
$ |
60,765 |
| |
|
|
|
|
|
|
|
|
|
|
|
| Costs and expenses: |
|
|
|
|
|
|
|
|
|
|
|
| Cost of sales |
|
16,029 |
|
|
11,604 |
|
|
30,935 |
|
|
22,687 |
| Selling, general and administrative |
|
12,604 |
|
|
8,728 |
|
|
24,965 |
|
|
17,859 |
| Acquisition and reorganization costs |
|
312 |
|
|
115 |
|
|
2,161 |
|
|
212 |
| Costs and expenses |
|
28,945 |
|
|
20,447 |
|
|
58,061 |
|
|
40,758 |
| |
|
|
|
|
|
|
|
|
|
|
|
| Operating income |
|
10,149 |
|
|
11,880 |
|
|
17,702 |
|
|
20,007 |
| Equity in income of joint ventures |
|
1,067 |
|
|
615 |
|
|
1,871 |
|
|
1,126 |
| Interest income (expense), net |
|
(863) |
|
|
13 |
|
|
(1,453) |
|
|
4 |
| Other income, net |
|
(9) |
|
|
(88) |
|
|
50 |
|
|
13 |
| |
|
|
|
|
|
|
|
|
|
|
|
| Income before taxes |
|
10,344 |
|
|
12,420 |
|
|
18,170 |
|
|
21,150 |
| Income taxes |
|
3,104 |
|
|
4,294 |
|
|
5,846 |
|
|
7,031 |
| |
|
|
|
|
|
|
|
|
|
|
|
| Net income |
|
7,240 |
|
|
8,126 |
|
|
12,324 |
|
|
14,119 |
| Less: Net income attributed to noncontrolling interest |
|
130 |
|
|
129 |
|
|
289 |
|
|
303 |
| |
|
|
|
|
|
|
|
|
|
|
|
| Net income attributed to Landauer, Inc. |
$ |
7,110 |
|
$ |
7,997 |
|
$ |
12,035 |
|
$ |
13,816 |
| |
|
|
|
|
|
|
|
|
|
|
|
| Net income per share attributable to Landauer, Inc. shareholders: |
|
|
|
|
|
|
|
|
|
|
|
| Basic |
$ |
0.76 |
|
$ |
0.85 |
|
$ |
1.28 |
|
$ |
1.48 |
| Weighted average basic shares outstanding |
|
9,361 |
|
|
9,332 |
|
|
9,347 |
|
|
9,322 |
| |
|
|
|
|
|
|
|
|
|
|
|
| Diluted |
$ |
0.75 |
|
$ |
0.85 |
|
$ |
1.27 |
|
$ |
1.47 |
| Weighted average diluted shares outstanding |
|
9,402 |
|
|
9,377 |
|
|
9,387 |
|
|
9,367 |
- more -
Landauer,
Inc.
Add
10
LANDAUER,
INC. AND SUBSIDIARIES
Consolidated Balance Sheets (Unaudited)
| |
|
|
|
|
|
| (Dollars in Thousands) |
March 31,
2012 |
|
September 30,
2011 |
| ASSETS |
|
|
|
|
|
| Current assets: |
|
|
|
|
|
| Cash and cash equivalents |
$ |
18,699 |
|
$ |
7,914 |
| Receivables, net of allowances of $849 and $794, respectively |
|
30,703 |
|
|
25,516 |
| Inventories |
|
7,896 |
|
|
8,286 |
| Prepaid income taxes |
|
991 |
|
|
4,921 |
| Prepaid expenses and other current assets |
|
4,582 |
|
|
4,005 |
| Current assets |
|
62,871 |
|
|
50,642 |
| Property, plant and equipment, at cost |
|
104,873 |
|
|
96,798 |
| Accumulated depreciation |
|
(51,747) |
|
|
(49,157) |
| Net property, plant and equipment |
|
53,126 |
|
|
47,641 |
| Equity in joint ventures |
|
10,375 |
|
|
10,699 |
| Goodwill |
|
107,151 |
|
|
39,962 |
| Intangible assets, net of accumulated amortization of $8,421 and $7,355, respectively |
|
39,418 |
|
|
10,908 |
| Dosimetry devices, net of accumulated depreciation of $10,491 and $9,728, respectively |
|
5,715 |
|
|
5,618 |
| Other assets |
|
5,776 |
|
|
3,186 |
| Assets |
$ |
284,432 |
|
$ |
168,656 |
| |
|
|
|
|
|
| LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
| Current liabilities: |
|
|
|
|
|
| Accounts payable |
$ |
7,121 |
|
$ |
5,457 |
| Dividends payable |
|
5,319 |
|
|
5,301 |
| Deferred contract revenues |
|
15,468 |
|
|
14,713 |
| Short-term debt |
|
0 |
|
|
19,805 |
| Accrued compensation and related costs |
|
6,259 |
|
|
5,607 |
| Other accrued expenses |
|
5,818 |
|
|
7,066 |
| Current liabilities |
|
39,985 |
|
|
57,949 |
| Non-current liabilities: |
|
|
|
|
|
| Long-term debt |
|
129,087 |
|
|
0 |
| Pension and postretirement obligations |
|
14,627 |
|
|
14,202 |
| Deferred income taxes |
|
14,314 |
|
|
12,805 |
| Other non-current liabilities |
|
1,249 |
|
|
1,292 |
| Non-current liabilities |
|
159,277 |
|
|
28,299 |
| Stockholders’ equity: |
|
|
|
|
|
| Preferred stock, $.10 par value per share, authorized 1,000,000 shares; none issued |
|
0 |
|
|
0 |
|
Common stock, $.10 par value per share, authorized
20,000,000 shares; 9,515,229 and
9,462,807 shares issued and outstanding at
March 31, 2012 and September 30, 2011,
respectively |
|
952 |
|
|
946 |
| Additional paid in capital |
|
35,207 |
|
|
33,791 |
| Accumulated other comprehensive loss |
|
(3,342) |
|
|
(3,129) |
| Retained earnings |
|
51,333 |
|
|
49,724 |
| Landauer, Inc. stockholders’ equity |
|
84,150 |
|
|
81,332 |
| Noncontrolling interest |
|
1,020 |
|
|
1,076 |
| Stockholders’ equity |
|
85,170 |
|
|
82,408 |
| Liabilities and Stockholders’ Equity |
$ |
284,432 |
|
$ |
168,656 |
- more -
Landauer,
Inc.
Add
11
LANDAUER,
INC. AND SUBSIDIARIES
Reconciliation of Net Income to Adjusted
Earnings
before Interest, Taxes, Depreciation and
Amortization
| |
Three Months Ended
March 31, |
| |
2012 |
|
2011 |
| Net income attributed to Landauer, Inc. |
$ |
7,110 |
|
$ |
7,997 |
| Add back: |
|
|
|
|
|
| Interest expense, net |
|
771 |
|
|
(13) |
| Income taxes |
|
3,104 |
|
|
4,294 |
| Depreciation and amortization |
|
2,674 |
|
|
1,806 |
| Earnings before interest, taxes, depreciation and amortization (EBITDA) |
$ |
13,659 |
|
$ |
14,084 |
| Adjustments: |
|
|
|
|
|
| Non-cash stock-based compensation expenses |
|
624 |
|
|
518 |
| IT platform enhancements expenses |
|
306 |
|
|
232 |
| Acquisition and reorganization costs |
|
312 |
|
|
115 |
| Sub-total adjustments |
|
1,242 |
|
|
865 |
|
Adjusted earnings before interest, taxes, depreciation
and amortization
(Adjusted EBITDA) |
$ |
14,901 |
|
$ |
14,949 |
| |
Six Months Ended
March 31, |
| |
2012 |
|
2011 |
| Net income attributed to Landauer, Inc. |
$ |
12,035 |
|
$ |
13,816 |
| Add back: |
|
|
|
|
|
| Interest expense, net |
|
1,299 |
|
|
(4) |
| Income taxes |
|
5,846 |
|
|
7,031 |
| Depreciation and amortization |
|
5,030 |
|
|
3,604 |
| Earnings before interest, taxes, depreciation and amortization (EBITDA) |
$ |
24,210 |
|
$ |
24,447 |
| Adjustments: |
|
|
|
|
|
| Non-cash stock-based compensation expenses |
|
1,454 |
|
|
945 |
| IT platform enhancements expenses |
|
588 |
|
|
646 |
| Acquisition and reorganization costs |
|
2,161 |
|
|
212 |
| Sub-total adjustments |
|
4,203 |
|
|
1,803 |
|
Adjusted earnings before interest, taxes, depreciation
and amortization
(Adjusted EBITDA) |
$ |
28,413 |
|
$ |
26,250 |
- more -
Landauer,
Inc.
Add
12
LANDAUER,
INC. AND SUBSIDIARIES
Reconciliation
of EPS to Adjusted EPS
| |
Three Months Ended
March 31, |
| |
2012 |
|
2011 |
| Net income attributed to Landauer, Inc. |
$ |
7,110 |
|
$ |
7,997 |
| |
|
|
|
|
|
| Sub-total adjustments |
|
1,242 |
|
|
865 |
| Income taxes on adjustments |
|
(373) |
|
|
(299) |
| Adjustments, net |
|
869 |
|
|
566 |
| |
|
|
|
|
|
| Adjusted net income |
$ |
7,979 |
|
$ |
8,563 |
| |
|
|
|
|
|
| Adjusted net income per diluted share |
$ |
0.85 |
|
$ |
0.91 |
| Weighted average diluted shares outstanding |
|
9,402 |
|
|
9,377 |
| |
Six Months Ended
March 31, |
| |
2012 |
|
2011 |
| Net income attributed to Landauer, Inc. |
$ |
12,035 |
|
$ |
13,816 |
| |
|
|
|
|
|
| Sub-total adjustments |
|
4,203 |
|
|
1,803 |
| Income taxes on adjustments |
|
(1,353) |
|
|
(599) |
| Adjustments, net |
|
2,850 |
|
|
1,204 |
| |
|
|
|
|
|
| Adjusted net income |
$ |
14,885 |
|
$ |
15,020 |
| |
|
|
|
|
|
| Adjusted net income per diluted share |
$ |
1.59 |
|
$ |
1.60 |
| Weighted average diluted shares outstanding |
|
9,387 |
|
|
9,367 |
Adjusted Free Cash Flow
| |
Six Months Ended
March 31, |
| |
2012 |
|
2011 |
| Adjusted EBITDA |
$ |
28,413 |
|
$ |
26,250 |
| Change in working capital |
|
745 |
|
|
(1,021) |
| Capital expenditures |
|
(7,358) |
|
|
(5,653) |
| Adjusted Free Cash Flow |
$ |
21,800 |
|
$ |
19,576 |
# # #
